Prescient Therapeutics Ltd

NEW
ASX:PTX (Australia)  
A$ 0.044 -0.0030 (-6.38%) Feb 28
At Loss
P/B:
2.32
Market Cap:
A$ 35.43M ($ 22.01M)
Enterprise V:
A$ 27.06M ($ 16.81M)
Volume:
244.65K
Avg Vol (2M):
432.55K
Trade In:
Volume:
244.65K
At Loss
Avg Vol (2M):
432.55K

Business Description

Description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 247.24
Equity-to-Asset 0.94
Debt-to-EBITDA -0.01
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 30.3
9-Day RSI 35.5
14-Day RSI 39.69
3-1 Month Momentum % 41.03
6-1 Month Momentum % 25
12-1 Month Momentum % 17.02

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 15.97
Quick Ratio 15.97
Cash Ratio 8.99

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -7.9

Profitability Rank

Name Current Vs Industry Vs History
ROE % -37.65
ROA % -34.35
ROIC % -165.81
3-Year ROIIC % 1189.35
ROC (Joel Greenblatt) % -254.29
ROCE % -39.39

Financials

ASX:PTX's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Prescient Therapeutics Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.009
Beta 0.16
3-Year Sharpe Ratio -0.49
3-Year Sortino Ratio -0.7
Volatility % 49.24
14-Day RSI 39.69
14-Day ATR (A$) 0.002521
20-Day SMA (A$) 0.0489
12-1 Month Momentum % 17.02
52-Week Range (A$) 0.037 - 0.066
Shares Outstanding (Mil) 805.32

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Prescient Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Prescient Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price (A$)
No Event Data

Prescient Therapeutics Ltd Frequently Asked Questions

What is Prescient Therapeutics Ltd(ASX:PTX)'s stock price today?
The current price of ASX:PTX is A$0.04. The 52 week high of ASX:PTX is A$0.07 and 52 week low is A$0.04.
When is next earnings date of Prescient Therapeutics Ltd(ASX:PTX)?
The next earnings date of Prescient Therapeutics Ltd(ASX:PTX) is .
Does Prescient Therapeutics Ltd(ASX:PTX) pay dividends? If so, how much?
Prescient Therapeutics Ltd(ASX:PTX) does not pay dividend.

Press Release

Subject Date
No Press Release